HEC88473 is an experimental dual GLP-1 and fibroblast growth factor 21 (FGF21) receptor agonist. It is developed by the Chinese company HEC Pharm for diabetes and non-alcoholic steatohepatitis.[1][2]
References edit
- ^ Pan, Qi; Lin, Shushan; Li, Yu; Liu, Liang; Li, Xiaoping; Gao, Xianglei; Yan, Jiangyu; Gu, Baohua; Chen, Xiaofeng; Li, Wenjia; Tang, Xinfa; Chen, Chao; Guo, Lixin (January 2021). "A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis". EBioMedicine. 63: 103202. doi:10.1016/j.ebiom.2020.103202. ISSN 2352-3964. PMC 7806870.
- ^ Negi, Chander K.; Babica, Pavel; Bajard, Lola; Bienertova-Vasku, Julie; Tarantino, Giovanni (January 2022). "Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease". Metabolism. 126: 154925. doi:10.1016/j.metabol.2021.154925.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |